Skip to main content
Premium Trial:

Request an Annual Quote

KineMed Collaborates With Pfizer on Proteomics Biomarkers

NEW YORK (GenomeWeb) – KineMed has signed a strategic deal with Pfizer to discover and develop new proteomics-based biomarkers using KineMed's protein activity kinetics tracking technology, the California-based company announced today.

Under the terms of the agreement, Pfizer has licensed KineMed's proteomics platform and the rights to discover, develop, and commercialize biomarkers. The partners will work together on discovery, while Pfizer will be responsible for developing and commercializing any biomarkers or companion diagnostics.

Pfizer will give KineMed an upfront payment and funding for R&D costs and KineMed will be eligible to receive further payments for meeting development and regulatory milestones. The amounts of the payments were not disclosed.

"We believe our kinetic biomarker platform provides real advantages over other approaches to biomarker discovery in de-risking and advancing medicines development, and this collaboration with Pfizer is an important step toward helping us realize the full potential of this technology," KineMed President Patrick Doyle said in a statement.

KineMed's platform uses mass spectroscopy and stable isotope labeling of protein turnover to provide rates of change in key proteins involved with therapeutic efficacy and target engagement, the firm said in a statement.

The strategic collaboration furthers the relationship between the two firms — in June 2014, they renewed a non-exclusive research collaboration on metabolic disease, particularly type 2 diabetes.

The Scan

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.